Alector to Participate in Key Healthcare Conferences
Alector, Inc. (NASDAQ: ALEC), a leading clinical-stage biotechnology firm specializing in immuno-neurology, has announced its strategic involvement in several major investor conferences. These events will enable Alector's management team to connect with investors, analysts, and industry experts, sharing valuable insights on their cutting-edge research and development initiatives.
Upcoming Investor Conferences
Alector is set to participate in the following notable conferences:
Morgan Stanley 22nd Annual Global Healthcare Conference
The company will take part in the Morgan Stanley 22nd Annual Global Healthcare Conference. Alector's management is scheduled for a fireside chat on September 5, 2024, at 7:45 a.m. ET. This annual gathering serves as a platform for industry leaders to discuss significant trends and advancements in healthcare.
H.C. Wainwright 26th Annual Global Investment Conference
Next, Alector will be featured at the H.C. Wainwright 26th Annual Global Investment Conference. The fireside chat is set for September 9, 2024, at 10:00 a.m. ET. This event draws a diverse array of investors eager to learn more about emerging companies like Alector.
2024 Cantor Global Healthcare Conference
Alector will also participate in the esteemed 2024 Cantor Global Healthcare Conference. On September 17, 2024, the management team will engage in another fireside chat at 9:45 a.m. ET, discussing the latest advancements in their clinical programs.
Webcasts and Presentations
A webcast of each presentation will be accessible on the “Events & Presentations” page within Alector's Investors section on their official website. These webcasts will be available for 90 days following the conferences, allowing stakeholders to revisit the discussions and insights shared during these events.
Alector's Mission
Alector is dedicated to innovating in the field of immuno-neurology, a groundbreaking approach aimed at treating neurodegenerative diseases by addressing immune dysfunction, which is often a fundamental cause of various debilitating brain disorders. The company has built a robust portfolio of programs that target the innate immune system, aiming to tackle genetic mutations that contribute to brain immune system dysfunction and enhance immune responses to emerging pathologies.
Research and Development Focus
Alector's pipeline includes candidates specifically designed to address conditions such as Alzheimer’s disease and frontotemporal dementia, particularly in genetically defined patient populations. The company's commitment to pioneering innovative therapeutic approaches positions it at the forefront of addressing significant unmet needs in the treatment of neurodegenerative diseases.
Contact Information for Alector
For further inquiries, investors and interested parties are encouraged to reach out to:
Alector Contacts:
Katie Hogan
Phone: 202-549-0557
Email: katie.hogan@alector.com
Media Inquiries
For any media-related questions, please contact:
Dan Budwick
Phone: 973-271-6085
Email: dan@1abmedia.com
Investor Relations
All communications regarding investor relations can be directed to:
Laura Perry
Phone: 212-600-1902
Email: alector@argotpartners.com
Frequently Asked Questions
What is Alector known for?
Alector is known for its innovative work in immuno-neurology, focusing on developing therapies for neurodegenerative diseases.
Where can I watch the investor presentations?
The presentations will be available via webcast on Alector's official website for 90 days following each event.
What type of diseases does Alector target?
Alector targets neurodegenerative diseases, including Alzheimer’s and frontotemporal dementia.
How can I contact Alector for more information?
Interested individuals can contact Alector through the investor relations or media contacts provided in their announcements.
What is the significance of the upcoming conferences for Alector?
Participating in these conferences allows Alector to showcase its innovations and engage directly with potential investors and stakeholders, fostering support and collaboration.